retatrutide clinical trial results 2024 2025 press release The Dosage Chart October 27, 2025: U.K. regulators

The atypical antipsychotic olanzapine causes weight gain by targeting serotonin receptor 2 C

Your Ivm provider can help you find the right approach for your goals

Evolution and challenges of new obesity drugs related to adverse effects and future direction Combatting obesity represents a major health dilemma, as it contributes to a heightened risk of disease, diminishes the quality of life, and can reduce life expectancy

But if you're on a GLP-1 medication Ozempic, Wegovy, Mounjaro, Trulicity, or any of the others becoming increasingly common across the UK you'll already know that your treatment comes with a few extra things to think about